Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

30.46
-1.6300-5.08%
Post-market: 30.460.00000.00%16:34 EDT
Volume:693.96K
Turnover:21.38M
Market Cap:2.67B
PE:-23.71
High:32.05
Open:31.90
Low:30.36
Close:32.09
52wk High:39.28
52wk Low:13.45
Shares:87.67M
Float Shares:81.82M
Volume Ratio:0.49
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2849
EPS(LYR):-1.2849
ROE:-10.92%
ROA:-8.92%
PB:2.61
PE(LYR):-23.71

Loading ...

IDEAYA Biosciences grants 49,000 inducement stock options; exercise price set at $32.09

Reuters
·
Yesterday

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Yesterday

Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 24

Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release

TIPRANKS
·
Mar 23

Ideaya Biosciences falls -6.0%

TIPRANKS
·
Mar 23

Analysts’ Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 23

J.P. Morgan Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 23

IDEAYA Biosciences: Operational Trial Delay but High Conviction Buy Ahead of Key Darovasertib Readout

TIPRANKS
·
Mar 23

IDEAYA forecasts OptimUM-02 trial database lock in April 2026

Reuters
·
Mar 22

IDEAYA Biosciences to host darovasertib OptimUM-02 topline results webcast and attend Bank of America health care conference

Reuters
·
Mar 22

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance From Phase 2/3 Optimum-02 Trial

THOMSON REUTERS
·
Mar 22

IDEAYA Biosciences to present three posters at AACR Annual Meeting

Reuters
·
Mar 18

IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities

TIPRANKS
·
Mar 17

Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Lantheus (LNTH)

TIPRANKS
·
Mar 09

BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892

Reuters
·
Mar 09

IDEAYA Biosciences reports first patient enrolled in Phase 1 IDE892 trial for MTAP-deleted solid tumors

Reuters
·
Mar 09

IDEAYA Biosciences Inc - Targets Cdkn2a Development Candidate Nomination in H2 2026 and Ind in H1 2027

THOMSON REUTERS
·
Mar 09

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Trial of Ide892, a Potential Best-in-Class Prmt5 Inhibitor for Mtap-Deleted Solid Tumors, and Provides Mtap and Cdkn2a Pipeline Update

THOMSON REUTERS
·
Mar 09

IDEAYA Biosciences Inc - Ide892 to Be Combined With Ide397 in Phase 1 Trial in Mid-2026

THOMSON REUTERS
·
Mar 09

IDEAYA Biosciences Director Jeffrey Stein Acquires Common Shares

Reuters
·
Mar 03